USPTO serial 79324525
ELATIVE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 27, 2022
- Examiner
- GILLES, DEBORAH LYNN MEINERS
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ELATIVE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ronald M. Kachmarik
Ronald M. Kachmarik Cooper Legal Group, LLC1388 Ridge Road, Unit 1Hinckley, OH 44233UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the prevention and treatment of liver diseases, cholesterol diseases, metabolic diseases, gastroenterological diseases, inflammatory diseases, auto-immune diseases and cancer diseases; chemical preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholesterol diseases, metabolic diseases , gastroenterological diseases, inflammatory diseases, auto-immune diseases and cancer diseases; organic biological preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholesterol diseases, metabolic diseases , gastroenterological diseases, inflammatory diseases, auto-immune diseases and cancer diseases; diagnostic preparations for medical use; diagnostic reagents for medical use | ACTIVE | — |
| 042 | Scientific research for medical purposes; pharmaceutical research and development services; conducting clinical trials for others for pharmaceutical products, in particular conducting clinical trials for others for determining the efficacy and safety of elafibranor; conducting clinical trials for others to determine the efficacy and safety of pharmaceutical products in the treatment of primary biliary cholangitis (PBC); conducting scientific studies and analyses in the field of pharmaceuticals and medicines; scientific research and development, namely providing information, results and data relating to scientific or medical research and development of pharmaceutical products, especially from an online searchable database; medical and scientific research, namely conducting clinical trials for others; pharmaceutical and biological development and research services for third parties; clinical research for others in the field of pharmaceuticals and medicines; evaluation of the efficacy of pharmaceutical products | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 19, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 14, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 25, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 25, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 27, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 27, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 27, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 19, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 12, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 12, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 29, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 29, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 22, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 9, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 8, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 7, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 7, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 25, 2022 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 8, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 4, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 4, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 25, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 24, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 17, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 12, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 8, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 5, 2021 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Oct 28, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |